This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Study of the Effect of Intramuscular Ephedrine on the Incidence of Nausea and Vomiting During Elective Cesarean Section

This study has been completed.
Sponsor:
Collaborator:
New York Presbyterian Hospital
Information provided by (Responsible Party):
Weill Medical College of Cornell University
ClinicalTrials.gov Identifier:
NCT00432991
First received: February 7, 2007
Last updated: April 14, 2017
Last verified: April 2017
  Purpose
The purpose of this research study is to investigate if the incidence of nausea and vomiting that subjects experience during and after a Cesarean section can be reduced by giving a shot of the drug ephedrine into the thigh muscle at the time of spinal anesthesia administration.

Condition Intervention Phase
Nausea Vomiting Cesarean Section Drug: Ephedrine [Synonyms: Ephedra, Ephedrinum] Drug: Saline Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: A Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Intramuscular Ephedrine on the Incidence of Perioperative Nausea and Vomiting During Elective Cesarean Section

Resource links provided by NLM:


Further study details as provided by Weill Medical College of Cornell University:

Primary Outcome Measures:
  • Pre-Induction Nausea Score [ Time Frame: immediately pre-induction ]
    Subject's self-rated nausea level on a scale of 0-3 immediately prior to induction of spinal anesthesia, where 0=no nausea, 1=mild nausea, 2=moderate nausea, and 3=severe nausea

  • Subject's Self-rated Intra-operative Nausea Level on a Scale of 0-3, Where 0=no Nausea, 1=Mild Nausea, 2=Moderate Nausea, and 3=Severe Nausea. [ Time Frame: intra-operation ]

    Subjects were asked to rate their nausea level on a scale of 0-3, where 0=no nausea, 1=mild nausea, 2=moderate nausea, and 3=severe nausea, five times during their procedure: 1) Immediately prior to skin incision, 2) immediately following delivery of the baby, 3) following reinternalization of the uterus, 4) following closure of the fascia, 5) following closure of the skin.

    The numbers given by the subject were then averaged to determine the average level of nausea intra-operatively for each subject.


  • Post-Operation Nausea Score [ Time Frame: post-operation ]

    Subjects were asked to rate their nausea level on a scale of 0-3, where 0=no nausea, 1=mild nausea, 2=moderate nausea, and 3=severe nausea two times after the conclusion of their surgery: 1) upon arrival in the PACU, and 2) immediately prior to discharge from the PACU.

    The numbers given by the subject were then averaged to determine the average level of nausea post-operative for each subject.



Enrollment: 53
Study Start Date: February 2007
Study Completion Date: September 2010
Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Saline Placebo
Drug: Saline Placebo 0.5 mL, IM (in the muscle), one time
Drug: Saline Placebo
0.5 mL, IM (in the muscle), one time
Experimental: IM Ephedrine
Drug: Ephedrine [Synonyms: Ephedra, Ephedrinum] 25 mg, IM (in the muscle), one time
Drug: Ephedrine [Synonyms: Ephedra, Ephedrinum]
25 mg, IM (in the muscle), one time

Detailed Description:
This research project is designed to study the medication ephedrine, when it is given as a routine part of the anesthesia for elective Cesarean section. Ephedrine is a medication that is widely used in labor and in vaginal and operative (Cesarean section) deliveries to help maintain a woman's blood pressure within its normal range, especially after spinal and epidural anesthesia has been administered. The purpose of this study is to determine if ephedrine, when given intramuscularly (<IM> as a shot in the muscle), at the time of spinal anesthesia administration, can help to decrease the incidence of nausea and vomiting subjects experience during and after a Cesarean section. This study will compare women who receive ephedrine to a similar group of women who receive a normal saline placebo. In addition to looking at the difference in the incidence of nausea and vomiting perioperatively, this study will also evaluate if the administration of IM ephedrine helps the baby to receive more blood from the placenta after anesthesia has been administered to the mother. This will be evaluated by performing a simple blood test, drawn from the umbilical cord, after the baby is born.
  Eligibility

Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Must be pregnant with a single baby
  • Must be at term in their pregnancy (estimated gestational age of at least 38 weeks)
  • Must be scheduled for an elective Cesarean section
  • Must be between 60-70" tall
  • Must be free of severe systemic disease (ASA class I or II)

Exclusion Criteria:

  • Contraindication to spinal anesthesia
  • Any allergy to any of the medications included in the study
  • History of pregnancy-induced hypertension or preeclampsia
  • History of preexisting hypertension
  • Diabetes mellitus
  • Hyperemesis gravidum
  • Previous perioperative nausea and vomiting
  • History of motion sickness
  • Women carrying a fetus with a known abnormality will also be excluded from the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00432991

Locations
United States, New York
New York-Presbyterian Hospital; Weill Medical College of Cornell
New York, New York, United States, 10021
Sponsors and Collaborators
Weill Medical College of Cornell University
New York Presbyterian Hospital
Investigators
Principal Investigator: Sharon Abramovitz, MD Anesthesiology; Weill Medical College of Cornell - New York Presbyterian Hospital
  More Information

Responsible Party: Weill Medical College of Cornell University
ClinicalTrials.gov Identifier: NCT00432991     History of Changes
Other Study ID Numbers: 0609008727
Study First Received: February 7, 2007
Results First Received: February 16, 2017
Last Updated: April 14, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Weill Medical College of Cornell University:
Nausea
Vomiting
Cesarean Section

Additional relevant MeSH terms:
Nausea
Vomiting
Signs and Symptoms, Digestive
Signs and Symptoms
Ephedrine
Pseudoephedrine
Central Nervous System Stimulants
Physiological Effects of Drugs
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Vasoconstrictor Agents
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Bronchodilator Agents
Anti-Asthmatic Agents
Respiratory System Agents
Nasal Decongestants

ClinicalTrials.gov processed this record on September 21, 2017